Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report)’s stock price traded down 2.6% during mid-day trading on Wednesday . The company traded as low as $10.07 and last traded at $10.07. 359 shares were traded during trading, a decline of 91% from the average session volume of 3,781 shares. The stock had previously closed at $10.34.
Innovent Biologics Price Performance
The firm has a fifty day simple moving average of $10.72 and a two-hundred day simple moving average of $10.87.
About Innovent Biologics
Innovent Biologics is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of high-quality biologic therapies. Founded in 2011 and headquartered in the Suzhou National Biotech R&D Park, the company specializes in innovative treatments across oncology, metabolic and ophthalmology indications. Innovent’s integrated model encompasses end-to-end capabilities, from early discovery and clinical development to large-scale manufacturing and market launch.
The company has built a diversified product portfolio that includes the anti-PD-1 monoclonal antibody sintilimab (Tyvyt), approved for lymphoma and non-small cell lung cancer in China, as well as multiple biosimilars such as IBI305 (a bevacizumab biosimilar) and IBI306 (an etanercept biosimilar).
See Also
- Five stocks we like better than Innovent Biologics
- Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak
- TeraWulf Bets on Power Infrastructure to Lead AI Build-Out
- Amazon’s Alexa for Shopping Strengthens an Already Strong Bull Case
- Keysight: The AI and Defense Stock Seeing Big Price Target Boosts
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
